Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-17T19:11:41.622Z Has data issue: false hasContentIssue false
  • English
  • Français

A new approach to the prevention of breast cancer

Published online by Cambridge University Press:  05 December 2011

H. Leon Bradlow  and
Jon J. Michnovicz
H. Leon Bradlow
Affiliation:
The Rockefeller University, 1230 York Avenue, New York, NY10021, U.S.A.
Jon J. Michnovicz
Affiliation:
The Rockefeller University, 1230 York Avenue, New York, NY10021, U.S.A.
Get access

Synopsis

While the role of oestrogens in breast cancer has been recognised for over a century, until recently our understanding of the mechanism by which they act has been limited, despite zealous efforts on the part of many investigators to seek for differences in oestrogen levels or metabolism in cancer patients. Since the initiation of breast cancer occurs many years before the detection of overt disease, it seems reasonable to suggest that these earlier studies may have been carried out at the wrong stage of the disease. Using a time invariant radiometric procedure, we have established that of the three principal sites of oestrogen metabolism at C-2, C-16α, and C-17, only C-16α hydroxylation is elevated in women with breast cancer. Further studies in women at high risk for breast cancer for familial reasons showed that they have an elevated rate of 16α-hydroxylation. Parallel studies in mice with high and low rates of spontaneous mammary tumour formation show a close parallelism between the extent of 16α-hydroxylation and tumour incidence. Studies of 16α-hydroxyoestrone, the product of 16α-hydroxylation, have demonstrated that it is a unique oestrogen, capable of binding irreversibly to the oestrogen receptor and permanently activating it. Studies on the effects of diet and drugs on the extent of C-2 and C-16α hydroxylation have shown that while the former reaction is easily increased or decreased, the latter is refractory to treatment and behaves like a constitutive enzyme. Thus, treatment with cimetidine, obesity, or high fat diets decrease the extent of C-2 hydroxylation, while high protein diets, hyperthyroidism, smoking, or dioxins increase C-2 hydroxylation. In contrast, 16α-hydroxylation is essentially unchanged in any of these conditions.

A link between increased C-2 hydroxylation and decreased levels of breast and endometrial cancer is suggested by epidemiological studies in smokers. Conversely, decreases in this reaction as in obesity are associated with increased risk for these tumours. The aim of these studies is to develop a safe prophylactic regimen which will increase C-2 hydroxylation, resulting in a decrease in active oestrogen and a lower tumour incidence.

Type
Research Article
Information
Proceedings of the Royal Society of Edinburgh, Section B: Biological Sciences , Volume 95: Oestrogen and the Human Breast , 1989 , pp. 77 - 86
Copyright
Copyright © Royal Society of Edinburgh 1989

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Basu, A. & Modak, M. J. 1987. An affinity labeling of Ras P21 protein and its use in the identification of Ras P21 in cellular and tissue extracts. Journal of Biological Chemistry 262, 2369–2373.CrossRefGoogle ScholarPubMed
Beatson, G. T. 1896. On the treatment of inoperable cases of carcinoma of the mammary. Suggestion for a new method with illustrative cases. Lancet 2, 104–107.CrossRefGoogle Scholar
Bittner, J. J. 1936. Some possible effects on nursing on the mammary gland in mice. Science 84, 162–164.CrossRefGoogle ScholarPubMed
Bradlow, H. L., Hershcopf, R. J., Martucci, C. P. & Fishman, J. 1985. Estradiol 16α-hydroxylation in the mouse correlates with mammary tumour incidence and presence of murine mammary tumor virus: a possible model for the hormonal etiology of breast cancer in humans. Proceedings of the National Academy of Science of the U.S.A. 82, 6295–6299.CrossRefGoogle Scholar
Cole, P., Cramer, D., Yen, R., Paffenbarger, R., MacMahon, B. & Brown, J. 1978. Estrogen profile of premenopausal women with breast cancer. Cancer Research 38, 745–748.Google ScholarPubMed
Fishman, J., Hellman, L., Zumoff, B. & Gallagher, T. F. 1965. Effect of thyroid on hydroxylation of estrogen in man. Journal of Clinical Endocrinology and Metabolism 25, 365–368.CrossRefGoogle ScholarPubMed
Fishman, J., Bradlow, H. L., Schneider, J., Anderson, K. E. & Kappas, A. 1980. Radiometric analysis of oxidation in man: Sex differences in estradiol metabolism. Proceedings of the National Academy of Science of the U.S.A. 77, 4957–4960.CrossRefGoogle ScholarPubMed
Fishman, J., Bradlow, H. L., Schneider, J., Anderson, K. E. & Martucci, C. 1980. Biological properties of 16α-hydroxyestrone: implications in estrogen physiology and pathophysiology. Journal of Clinical Endocrinology and Metabolism 51, 611–615.CrossRefGoogle Scholar
Ford, H. C., Lee, E. & Engel, L. L. 1979. Circannual variation and genetic regulation of hepatic testosterone hydroxylase activities in inbred strains of mice. Endocrinology 104, 857–861.CrossRefGoogle ScholarPubMed
Gierthy, J. F., Lincoln, D. W., Kampcik, J. J., Dickerman, H. W., Bradlow, H. L., Niwa, T. & Swaneck, G. E. 1988. Enhancement of 2- and 16α-estradiol hydroxylation in MCF-7 human breast cancer cell lines by 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin. Biochemical and Biophysical Research Communications 157, 515–520.CrossRefGoogle Scholar
Graham, M. J., Lucier, G. W., Linko, P., Maronpot, R. R. & Goldstein, J. A. 1988. Increase in cytochrome P-450 mediated 17β-estradiol 2-hydroxylase activity in rat liver microsomes after both acute administration and subchronic administration of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin in a two-stage hepatocarcinogenic model. Carcinogenesis 9, 1935–1941.CrossRefGoogle Scholar
Hershcopf, R. J. & Bradlow, H. L. 1987. Obesity, diet, endogenous estrogens, and the risk of hormone sensitive cancers. American Journal of Clinical Nutrition 45, 283–289.Google Scholar
Jones, M. K., Ramsey, I. D., Collins, W. P. & Dyer, G. I. 1977. The relationship of plasma prolactin to 17-β oestradiol in women with tumors of the breast. European Journal of Cancer 13, 1109–1112.CrossRefGoogle Scholar
Lesko, S. M., Rosenberg, L., Kaufman, D. W. et al. 1985. Cigarette smoking and the risk of endometrial cancer. New England Journal of Medicine 313, 593–596.CrossRefGoogle ScholarPubMed
Lustig, R. H., Mobbs, C. V., Pfaff, D. W. & Fishman, J. 1989. Temporal actions of 16α-hydroxylase in the rat: comparisons of lordosis dynamics with other estrogen metabolites and between sexes. Journal of Steroid Biochemistry, in press.CrossRefGoogle Scholar
Martucci, C. & Fishman, J. 1979. Impact of continuously administered catechol estrogens on uterine growth and LH secretion. Endocrinology 105, 1288–1292.Google Scholar
Michnovicz, J. J., Hershcopf, R. J., Naganuma, H., Bradlow, H. L. & Fishman, J. 1986. Increased 2-hydroxylation of estradiol of as possible mechanism for the anti-estrogenic effect of cigarette smoking. New England Journal of Medicine 315, 1305–1309.CrossRefGoogle ScholarPubMed
Michnovicz, J. J., Naganuma, H., Hershcopf, R. J., Bradlow, H. L. & Fishman, J. 1988. Increased urinary catecholestrogen excretion in female smokers. Steroids 52, 69–83.CrossRefGoogle ScholarPubMed
Musey, P. I., Collins, D. C., Bradlow, H. L., Gould, K. G. & Preedy, J. R. 1987. Effect of diet on oxidationof 17β-estradiol in vivo. Journal of Clinical Endocrinology and Metabolism 65, 792–795.CrossRefGoogle Scholar
O'Connell, D. L., Hulka, B. S., Chambless, L. E., Wilkinson, W. E. & Deubner, D. C. 1987. Cigarette smoking, alcohol consumption, and breast cancer risk. Journal of the National Cancer Institute 78, 229–234.Google ScholarPubMed
Osborne, M. P., Karmali, R. A., Hershcopf, R. J., Bradlow, H. L. & Fishman, J. 1988. Omega-3 fatty acids: modulation of estrogen metabolism and potential for breast cancer prevention. Cancer Investigation 8, 629–631.CrossRefGoogle Scholar
Pasleau, F., Kolodeizi-Mehaignow, C. & Gielen, J. E. 1984. Genetic regulations of hepatic steroid 16a-hydroxylase activities in inbred strains of mice. Endocrinology 115, 1371–1379.CrossRefGoogle ScholarPubMed
Peden, N. R., Cargill, J. M., Browning, C. K., Sanders, J. H. B. & Wormsley, K. G. 1979. Male sexual dysfunction during treatment with cimetidine. British Medical Journal 1, 659.CrossRefGoogle ScholarPubMed
Schneider, J., Kinne, D., Fracchia, A., Pierce, V., Anderson, K. E., Bradlow, H. L. & Fishman, J. 1982. Abnormal oxidative metabolism of estradiol in women with breast cancer. Proceedings of the National Academy of Science of the U.S.A. 79, 3047–3051.CrossRefGoogle ScholarPubMed
Schneider, J., Bradlow, H. L., Strain, G., Levin, J., Anderson, K. & Fishman, J. 1983. Effect of obesity on estradiol metabolism: decreased formation of nonuterotropic metabolites. Journal of Clinical Endocrinology and Metabolism. 56, 973–978.CrossRefGoogle ScholarPubMed
Spence, R. W. & Celestin, L. R. 1979. Gynecomastia associated with cimetidine. Gut 20, 154–157.CrossRefGoogle ScholarPubMed
Swaneck, G. & Fishman, J. 1988. Covalent binding of the endogenous estrogen 16α-hydroxyestrone to estradiol receptor in human breast cancer cells: Characterization and intranuclear localization. Proceedings of the National Academy of Science of the U.S.A. 85, 7831–35.CrossRefGoogle Scholar
Watson, J. R., Rible, L. & Taylor, B. A. 1977. The response of recombinant inbred strains of mice to bacterial lipopolysaccharides. Journal of Immunology 118, 2088–2093.CrossRefGoogle ScholarPubMed
Yu, S. & Fishman, J. 1985. Interactions of histones with estrogens. Covalent adduct formation with 16α-hydroxyestrone. Biochemistry 29, 8017–8021.CrossRefGoogle Scholar
Zumoff, B., Fishman, J., Bradlow, H. L. & Hellman, L. 1975. Hormone profiles in hormone dependent cancers. Cancer Research 35, 3365–3373.Google ScholarPubMed